세계 시토메갈로바이러스 치료 시장 - 점유율, 시장 규모, 동향, 산업 분석 보고서 : 약제별, 용도별, 유통 채널별, 지역별 부문 예측(2024-2032년)

The global Cytomegalovirus Treatment market size is expected to reach USD 1,035.16 million by 2032, according to a new study by Polaris Market Research. The report "Cytomegalovirus Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug (Ganciclovir, Valganciclovir, Cidofovir, Foscarnet, Others); By Application; By Distribution Channel; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Innovative therapeutic approaches are propelling robust growth in the Cytomegalovirus (CMV) Treatment Market. The market is transforming with novel strategies in antiviral drug development, immunotherapies, and targeted treatments. Adoptive T-cell transfer and immune modulators are gaining recognition for their potential to boost immune responses against CMV infections. Ongoing research into advanced drug formulations and combination therapies is generating more effective and targeted options. The CMV treatment market is adapting to the demand for advanced and patient-centric solutions, showcasing the synergy between scientific advancements and therapeutic innovation in addressing complexities associated with cytomegalovirus infections.

Recognizing the public health impact of CMV infections, governments globally are actively allocating funds for research, diagnosis, and advanced treatment solutions. These strategic efforts focus on increasing awareness, ensuring early detection, and promoting accessibility to cutting-edge therapies. Financial support for research and development, particularly in antiviral drugs like Ganciclovir, elevates the standard of CMV treatment. Government-led programs also target specific challenges in vulnerable populations, fostering collaborative advancements in the CMV treatment landscape and contributing to broader global public health goals.

Precise and rapid tools like nucleic acid amplification assays and serological tests enable early and accurate CMV detection, driving demand for treatments such as Ganciclovir. Point-of-care testing and sophisticated imaging modalities further enhance diagnostic capabilities, opening new avenues for timely CMV identification. The synergy between advanced diagnostics and treatment modalities reshapes patient care, offering personalized therapeutic approaches. With ongoing technological evolution, the CMV treatment market is set to witness expanded growth opportunities, emphasizing the central role of innovation in enhancing overall patient outcomes.

The shift towards personalized healthcare tailors treatment plans to individual needs, enhancing adherence and addressing CMV infection complexities. Innovative therapies prioritize minimizing side effects and improving outcomes, while patient-friendly administration methods and combination therapies contribute to the evolving CMV treatment landscape. Aligned with the trend of patient-centric care, the market holds promise for advancing and optimizing treatments for cytomegalovirus infections.

Cytomegalovirus Treatment Market Report Highlights

In 2023, the ganciclovir segment accounted for significant market share owing to antiviral efficacy, selective viral targeting, and clinical effectiveness.

In 2023, the stem cell transplantation segment accounted for significant market share owing to elevated risk of CMV reactivation and need for improving overall outcomes.

In 2023, the hospital pharmacy segment held significant revenue share owing to continuous diagnosis and monitoring of patients, and ease of access within healthcare units.

In 2023, North America region dominated the global market due to prevalence and incidence of CMV infections, and research and development.

The market is highly competitive owing to the existence of market players with a global presence, including Clinigen Group, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Gilead Sciences, Inc., Takeda Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. among others.

Polaris Market Research has segmented the Cytomegalovirus Treatment market report based on drug, application, distribution channel, and region:

Cytomegalovirus Treatment, Drug Outlook (Revenue - USD Million, 2019 - 2032)

• Ganciclovir
• Valganciclovir
• Cidofovir
• Foscarnet
• Others

Cytomegalovirus Treatment, Application Outlook (Revenue - USD Million, 2019 - 2032)

• Organ Transplantation
• Stem Cell Transplantation
• Congenital CMV Infection
• Others

Cytomegalovirus Treatment, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

• Hospital Pharmacy
• Retail Pharmacy
• Others

Cytomegalovirus Treatment, Regional Outlook (Revenue - USD Million, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• France
• Germany
• UK
• Italy
• Netherlands
• Spain
• Russia
• Asia Pacific
• Japan
• China
• India
• Malaysia
• Indonesia
• South Korea
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East & Africa
• Saudi Arabia
• UAE
• Israel
• South Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Cytomegalovirus Treatment Market Insights

• 4.1. Cytomegalovirus Treatment Market - Distribution Channel Snapshot
• 4.2. Cytomegalovirus Treatment Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing incidence of cytomegalovirus infections is projected to spur the product demand
    • 4.2.1.2. Rising transplantation activities is expected to drive cytomegalovirus treatment market growth
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. High cost of treatment is likely to impede the market growth
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Cytomegalovirus Treatment Market Distribution Channel Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Cytomegalovirus Treatment Market, by Drug

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
• 5.3. Ganciclovir
  • 5.3.1. Global Cytomegalovirus Treatment Market, by Ganciclovir, by Region, 2019-2032 (USD Million)
• 5.4. Valganciclovir
  • 5.4.1. Global Cytomegalovirus Treatment Market, by Valganciclovir, by Region, 2019-2032 (USD Million)
• 5.5. Cidofovir
  • 5.5.1. Global Cytomegalovirus Treatment Market, by Cidofovir, by Region, 2019-2032 (USD Million)
• 5.6. Foscarnet
  • 5.6.1. Global Cytomegalovirus Treatment Market, by Foscarnet, by Region, 2019-2032 (USD Million)
• 5.7. Others
  • 5.7.1. Global Cytomegalovirus Treatment Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Cytomegalovirus Treatment Market, by Application

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
• 6.3. Organ Transplantation
  • 6.3.1. Global Cytomegalovirus Treatment Market, by Organ Transplantation, by Region, 2019-2032 (USD Million)
• 6.4. Stem Cell Transplantation
  • 6.4.1. Global Cytomegalovirus Treatment Market, by Stem Cell Transplantation, by Region, 2019-2032 (USD Million)
• 6.5. Congenital CMV Infection
  • 6.5.1. Global Cytomegalovirus Treatment Market, by Congenital CMV Infection, by Region, 2019-2032 (USD Million)
• 6.6. Others
  • 6.6.1. Global Cytomegalovirus Treatment Market, by Others, by Region, 2019-2032 (USD Million)

7. Global Cytomegalovirus Treatment Market, by Distribution Channel

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
• 7.3. Hospital Pharmacy
  • 7.3.1. Global Cytomegalovirus Treatment Market, by Hospital Pharmacy, By Region, 2019-2032 (USD Million)
• 7.4. Retail Pharmacy
  • 7.4.1. Global Cytomegalovirus Treatment Market, by Retail Pharmacy, By Region, 2019-2032 (USD Million)
• 7.5. Others
  • 7.5.1. Global Cytomegalovirus Treatment Market, by Others, By Region, 2019-2032 (USD Million)

8. Global Cytomegalovirus Treatment Market, by Geography

• 8.1. Key findings
• 8.2. Introduction
  • 8.2.1. Cytomegalovirus Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
• 8.3. Cytomegalovirus Treatment Market - North America
  • 8.3.1. North America: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
  • 8.3.2. North America: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.3.3. North America: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.3.4. Cytomegalovirus Treatment Market - U.S.
    • 8.3.4.1. U.S.: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.3.4.2. U.S.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.3.4.3. U.S.: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.3.5. Cytomegalovirus Treatment Market - Canada
    • 8.3.5.1. Canada: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.3.5.2. Canada.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.3.5.3. Canada: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
• 8.4. Cytomegalovirus Treatment Market - Europe
  • 8.4.1. Europe: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
  • 8.4.2. Europe.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.4.3. Europe: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.4.4. Cytomegalovirus Treatment Market - UK
    • 8.4.4.1. UK: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.4.4.2. UK.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.4.4.3. UK: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.4.5. Cytomegalovirus Treatment Market - France
    • 8.4.5.1. France: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.4.5.2. France.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.4.5.3. France: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.4.6. Cytomegalovirus Treatment Market - Germany
    • 8.4.6.1. Germany: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.4.6.2. Germany.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.4.6.3. Germany: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.4.7. Cytomegalovirus Treatment Market - Italy
    • 8.4.7.1. Italy: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.4.7.2. Italy.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.4.7.3. Italy: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.4.8. Cytomegalovirus Treatment Market - Spain
    • 8.4.8.1. Spain: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.4.8.2. Spain.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.4.8.3. Spain: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.4.9. Cytomegalovirus Treatment Market - Netherlands
    • 8.4.9.1. Netherlands: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.4.9.2. Netherlands.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.4.9.3. Netherlands: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.4.10. Cytomegalovirus Treatment Market - Russia
    • 8.4.10.1. Russia: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.4.10.2. Russia.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.4.10.3. Russia: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
• 8.5. Cytomegalovirus Treatment Market - Asia Pacific
  • 8.5.1. Asia Pacific: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
  • 8.5.2. Asia Pacific.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.5.3. Asia Pacific: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.5.4. Cytomegalovirus Treatment Market - China
    • 8.5.4.1. China: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.5.4.2. China.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.5.4.3. China: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.5.5. Cytomegalovirus Treatment Market - India
    • 8.5.5.1. India: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.5.5.2. India.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.5.5.3. India: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.5.6. Cytomegalovirus Treatment Market - Malaysia
    • 8.5.6.1. Malaysia: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.5.6.2. Malaysia.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.5.6.3. Malaysia: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.5.7. Cytomegalovirus Treatment Market - Japan
    • 8.5.7.1. Japan: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.5.7.2. Japan.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.5.7.3. Japan: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.5.8. Cytomegalovirus Treatment Market - Indonesia
    • 8.5.8.1. Indonesia: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.5.8.2. Indonesia.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.5.8.3. Indonesia: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.5.9. Cytomegalovirus Treatment Market - South Korea
    • 8.5.9.1. South Korea: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.5.9.2. South Korea.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.5.9.3. South Korea: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
• 8.6. Cytomegalovirus Treatment Market - Middle East & Africa
  • 8.6.1. Middle East & Africa: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
  • 8.6.2. Middle East & Africa.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.6.3. Middle East & Africa: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.6.4. Cytomegalovirus Treatment Market - Saudi Arabia
    • 8.6.4.1. Saudi Arabia: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.6.4.2. Saudi Arabia.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.6.4.3. Saudi Arabia: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.6.5. Cytomegalovirus Treatment Market - UAE
    • 8.6.5.1. UAE: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.6.5.2. UAE.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.6.5.3. UAE: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.6.6. Cytomegalovirus Treatment Market - Israel
    • 8.6.6.1. Israel: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.6.6.2. Israel.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.6.6.3. Israel: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.6.7. Cytomegalovirus Treatment Market - South Africa
    • 8.6.7.1. South Africa: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.6.7.2. South Africa.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.6.7.3. South Africa: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
• 8.7. Cytomegalovirus Treatment Market - Latin America
  • 8.7.1. Latin America: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
  • 8.7.2. Latin America.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.7.3. Latin America: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.7.4. Cytomegalovirus Treatment Market - Mexico
    • 8.7.4.1. Mexico: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.7.4.2. Mexico.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.7.4.3. Mexico: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.7.5. Cytomegalovirus Treatment Market - Brazil
    • 8.7.5.1. Brazil: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.7.5.2. Brazil.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.7.5.3. Brazil: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.7.6. Cytomegalovirus Treatment Market - Argentina
    • 8.7.6.1. Argentina: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.7.6.2. Argentina.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.7.6.3. Argentina: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)

9. Competitive Landscape

• 9.1. Expansion and Acquisition Analysis
  • 9.1.1. Expansion
  • 9.1.2. Acquisitions
• 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

• 10.1. Bayer AG
  • 10.1.1. Company Overview
  • 10.1.2. Financial Performance
  • 10.1.3. Product Benchmarking
  • 10.1.4. Recent Development
• 10.2. Bristol Myers Squibb
  • 10.2.1. Company Overview
  • 10.2.2. Financial Performance
  • 10.2.3. Product Benchmarking
  • 10.2.4. Recent Development
• 10.3. Chimerix
  • 10.3.1. Company Overview
  • 10.3.2. Financial Performance
  • 10.3.3. Product Benchmarking
  • 10.3.4. Recent Development
• 10.4. Clinigen Group
  • 10.4.1. Company Overview
  • 10.4.2. Financial Performance
  • 10.4.3. Product Benchmarking
  • 10.4.4. Recent Development
• 10.5. Eli Lilly and Company
  • 10.5.1. Company Overview
  • 10.5.2. Financial Performance
  • 10.5.3. Product Benchmarking
  • 10.5.4. Recent Development
• 10.6. F. Hoffmann-La Roche Ltd
  • 10.6.1. Company Overview
  • 10.6.2. Financial Performance
  • 10.6.3. Product Benchmarking
  • 10.6.4. Recent Development
• 10.7. Fresenius Kabi
  • 10.7.1. Company Overview
  • 10.7.2. Financial Performance
  • 10.7.3. Product Benchmarking
  • 10.7.4. Recent Development
• 10.8. Genentech, Inc.
  • 10.8.1. Company Overview
  • 10.8.2. Financial Performance
  • 10.8.3. Product Benchmarking
  • 10.8.4. Recent Development
• 10.9. Gilead Sciences, Inc
  • 10.9.1. Company Overview
  • 10.9.2. Financial Performance
  • 10.9.3. Product Benchmarking
  • 10.9.4. Recent Development
• 10.10. GlaxoSmithKline plc
  • 10.10.1. Company Overview
  • 10.10.2. Financial Performance
  • 10.10.3. Product Benchmarking
  • 10.10.4. Recent Development
• 10.11. Merck & Co., Inc.
  • 10.11.1. Company Overview
  • 10.11.2. Financial Performance
  • 10.11.3. Product Benchmarking
  • 10.11.4. Recent Development
• 10.12. Pfizer Inc
  • 10.12.1. Company Overview
  • 10.12.2. Financial Performance
  • 10.12.3. Product Benchmarking
  • 10.12.4. Recent Development
• 10.13. Takeda Pharmaceuticals
  • 10.13.1. Company Overview
  • 10.13.2. Financial Performance
  • 10.13.3. Product Benchmarking
  • 10.13.4. Recent Development
• 10.14. Teva Pharmaceutical Industries Ltd.
  • 10.14.1. Company Overview
  • 10.14.2. Financial Performance
  • 10.14.3. Product Benchmarking
  • 10.14.4. Recent Development
• 10.15. Thermo Fisher Scientific
  • 10.15.1. Company Overview
  • 10.15.2. Financial Performance
  • 10.15.3. Product Benchmarking
  • 10.15.4. Recent Development